<DOC>
	<DOCNO>NCT01480622</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic profile tenofovir disoproxil fumarate ( TDF ) 300 mg Chinese subject support registration compound People 's Republic China . This open-label , single group , single repeat dose study without placebo healthy male female subject . Pharmacokinetic sample enable measurement plasma concentration tenofovir conduct 60-h period single dose steady state . The duration study approximately 7 week screen follow-up .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Profiles Tenofovir Disoproxil Fumarate ( TDF ) 300 mg Healthy Chinese Subjects</brief_title>
	<detailed_description>This open-label , single group , single repeat dose study placebo control healthy Chinese subject conduct single centre . The study include screen visit , single repeat dose session follow-up contact . The screen visit conduct 28 day prior first dose treatment period 1 . Screening assessment occur indicated Time Events Table . Subjects meet inclusion/exclusion criterion admit study centre Day -1 undergo baseline procedure single dose session . Study medication administer follow morning ( Day 1 ) single dose phase . Subjects require fast least 8 h ( overnight ) prior dose 4 h dosing . Pharmacokinetic sample take Day 3 . The repeat dose session begin Day 4 . Subjects receive daily dose TDF 300 mg fast state morning 7 day . Subjects require fast least 8 h ( overnight ) prior dose Day 8 Day 9 , least 8 h ( overnight ) prior dose 4 h dose Day 10 . A trough pharmacokinetic sample collect dosing Day 8 , Day 9 series sample take Day 10 Day 12 . Subjects remain in-house evening dosing ( Day -1 ) final pharmacokinetic sample collect Day 12 final safety assessment complete Day 13 . Then subject discharge study centre Investigator 's discretion . Subjects complete dose session require visit study centre follow-up visit , unless Investigator determines necessary safety reason . All subject receive follow-up contact telephone visit 7 day last dosing collect information concomitant medication take AEs experience since last visit . The total duration subject 's participation , screen follow-up contact , approximately 7 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Healthy , determine responsible experienced physician Male female 18 45 year age Body weight &gt; 50 kg ( 110 lb ) males &gt; 45 kg ( 100 lb ) female , body mass index ( BMI ) 19.0 24.0 kg/m2 Positive result hepatitis B , hepatitis C HIV screen Current chronic history liver disease , know hepatic biliary abnormality Positive urine drug screen breath alcohol test screen prior dose Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>healthy subject</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>hepatitis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>